Can a tiny company in a New Jersey suburb give Roche Diagnostics and Affymetrix — or any other company trying to sell cytochrome P450 tests — a run for their money?

In the wake of the US Food and Drug Administration’s decision not to allow the Swiss diagnostic giant to market its Affy-made AmpliChip as an analyte-specific reagent in the United States [see 11/6/03 SNPtech Pharmacogenomics Reporter], the answer just may be yes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.